Cargando…

Amblyopia screening effectiveness at 3–4 years old: a cohort study

OBJECTIVE: To study the effectiveness of amblyopia screening at ages 3–4. METHODS AND ANALYSIS: From a population with no previous screening, a cohort of 2300 children with 3–4 years old attending school (91% of children this age attend school in Portugal), were submitted to a complete ophthalmologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guimaraes, Sandra, Soares, Andreia, Freitas, Cristina, Barros, Pedro, Leite, Ricardo Dourado, Costa, Patrício Soares, Silva, Eduardo D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783520/
https://www.ncbi.nlm.nih.gov/pubmed/33437872
http://dx.doi.org/10.1136/bmjophth-2020-000599
_version_ 1783632133309333504
author Guimaraes, Sandra
Soares, Andreia
Freitas, Cristina
Barros, Pedro
Leite, Ricardo Dourado
Costa, Patrício Soares
Silva, Eduardo D
author_facet Guimaraes, Sandra
Soares, Andreia
Freitas, Cristina
Barros, Pedro
Leite, Ricardo Dourado
Costa, Patrício Soares
Silva, Eduardo D
author_sort Guimaraes, Sandra
collection PubMed
description OBJECTIVE: To study the effectiveness of amblyopia screening at ages 3–4. METHODS AND ANALYSIS: From a population with no previous screening, a cohort of 2300 children with 3–4 years old attending school (91% of children this age attend school in Portugal), were submitted to a complete ophthalmological evaluation. Amblyopia was diagnosed, treated and followed. Amblyopia prevalence, treatment effectiveness, absolute risk reduction (ARR), number needed to screen (NNS) and relative risk reduction (RRR) were estimated. RESULTS: Past/present history of amblyopia was higher than 3.1%–4.2%, depending on amblyopia definition normatives. Screening at age 3–4, had estimated ARR=2.09% (95% CI 1.50% to 2.68%) with a reduced risk of amblyopia in adulthood of 87% (RRR). NNS was 47.8 (95% CI 37.3 to 66.7). Treatment effectiveness of new diagnosis was 88% (83% if we include children already followed). 91% of new amblyopia diagnoses were refractive (of which 100% surpassed amblyopia Multi-Ethnic Pediatric Eye Disease Study criteria after treatment), while most strabismic amblyopias were already treated or undertreatment. Only 30% of children with refractive amblyopia risk factors that were not followed by an ophthalmologist, ended up having amblyopia at age 3–4. Eye patch was needed equally in new-diagnosis versus treated-earlier refractive amblyopia. CONCLUSIONS: Screening amblyopia in a whole-population setting at age 3–4 is highly effective. For each 48 children screened at age 3–4, one amblyopia is estimated to be prevented in the future (NNS). Screening earlier may lead to overdiagnosis and overtreatments: Treating all new diagnosis before age 3–4 would have a maximal difference in ARR of 0.3%, with the possible burden of as much as 70% children being unnecessary treated before age 3–4. Involving primary care, with policies for timely referral of suspicious/high-risk preverbal children, plus whole screening at age 3–4 seems a rational/effective way of controlling amblyopia.
format Online
Article
Text
id pubmed-7783520
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-77835202021-01-11 Amblyopia screening effectiveness at 3–4 years old: a cohort study Guimaraes, Sandra Soares, Andreia Freitas, Cristina Barros, Pedro Leite, Ricardo Dourado Costa, Patrício Soares Silva, Eduardo D BMJ Open Ophthalmol Paediatric Ophthalmology OBJECTIVE: To study the effectiveness of amblyopia screening at ages 3–4. METHODS AND ANALYSIS: From a population with no previous screening, a cohort of 2300 children with 3–4 years old attending school (91% of children this age attend school in Portugal), were submitted to a complete ophthalmological evaluation. Amblyopia was diagnosed, treated and followed. Amblyopia prevalence, treatment effectiveness, absolute risk reduction (ARR), number needed to screen (NNS) and relative risk reduction (RRR) were estimated. RESULTS: Past/present history of amblyopia was higher than 3.1%–4.2%, depending on amblyopia definition normatives. Screening at age 3–4, had estimated ARR=2.09% (95% CI 1.50% to 2.68%) with a reduced risk of amblyopia in adulthood of 87% (RRR). NNS was 47.8 (95% CI 37.3 to 66.7). Treatment effectiveness of new diagnosis was 88% (83% if we include children already followed). 91% of new amblyopia diagnoses were refractive (of which 100% surpassed amblyopia Multi-Ethnic Pediatric Eye Disease Study criteria after treatment), while most strabismic amblyopias were already treated or undertreatment. Only 30% of children with refractive amblyopia risk factors that were not followed by an ophthalmologist, ended up having amblyopia at age 3–4. Eye patch was needed equally in new-diagnosis versus treated-earlier refractive amblyopia. CONCLUSIONS: Screening amblyopia in a whole-population setting at age 3–4 is highly effective. For each 48 children screened at age 3–4, one amblyopia is estimated to be prevented in the future (NNS). Screening earlier may lead to overdiagnosis and overtreatments: Treating all new diagnosis before age 3–4 would have a maximal difference in ARR of 0.3%, with the possible burden of as much as 70% children being unnecessary treated before age 3–4. Involving primary care, with policies for timely referral of suspicious/high-risk preverbal children, plus whole screening at age 3–4 seems a rational/effective way of controlling amblyopia. BMJ Publishing Group 2021-01-04 /pmc/articles/PMC7783520/ /pubmed/33437872 http://dx.doi.org/10.1136/bmjophth-2020-000599 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Paediatric Ophthalmology
Guimaraes, Sandra
Soares, Andreia
Freitas, Cristina
Barros, Pedro
Leite, Ricardo Dourado
Costa, Patrício Soares
Silva, Eduardo D
Amblyopia screening effectiveness at 3–4 years old: a cohort study
title Amblyopia screening effectiveness at 3–4 years old: a cohort study
title_full Amblyopia screening effectiveness at 3–4 years old: a cohort study
title_fullStr Amblyopia screening effectiveness at 3–4 years old: a cohort study
title_full_unstemmed Amblyopia screening effectiveness at 3–4 years old: a cohort study
title_short Amblyopia screening effectiveness at 3–4 years old: a cohort study
title_sort amblyopia screening effectiveness at 3–4 years old: a cohort study
topic Paediatric Ophthalmology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783520/
https://www.ncbi.nlm.nih.gov/pubmed/33437872
http://dx.doi.org/10.1136/bmjophth-2020-000599
work_keys_str_mv AT guimaraessandra amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT soaresandreia amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT freitascristina amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT barrospedro amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT leitericardodourado amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT costapatriciosoares amblyopiascreeningeffectivenessat34yearsoldacohortstudy
AT silvaeduardod amblyopiascreeningeffectivenessat34yearsoldacohortstudy